

Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitors, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients with Chronic Kidney Disease or Heart Failure in the United Kingdom

Journal of the American Heart Association

8, e012655

DOI: [10.1161/jaha.119.012655](https://doi.org/10.1161/jaha.119.012655)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. <i>Journal of the American Heart Association</i> , 2019, 8, e012655.	1.6	44
2	Real-World Associations Between Renin-Angiotensin-Aldosterone System Inhibition Therapy, Hyperkalemia, and Outcomes: A Clinical and Scientific Call to Action. <i>Journal of the American Heart Association</i> , 2019, 8, e014845.	1.6	5
3	Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in <sc>Italy</sc>: a propensity-matched study. <i>European Journal of Heart Failure</i> , 2020, 22, 2049-2055.	2.9	25
4	Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. <i>International Journal of Clinical Practice</i> , 2021, 75, e13941.	0.8	4
5	Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. <i>Journal of Human Hypertension</i> , 2021, 35, 499-509.	1.0	14
6	Impact of a pharmacist-based multidimensional intervention aimed at decreasing the risk of hyperkalemia in heart failure patients: A Latin-American experience. <i>International Journal of Cardiology</i> , 2021, 329, 136-143.	0.8	2
7	Hyperkalaemia in Heart Failure. <i>Cardiac Failure Review</i> , 2021, 7, e10.	1.2	4
8	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. <i>Drugs</i> , 2021, 81, 1243-1255.	4.9	2
9	Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2114-2122.	1.4	15
10	Use of sodium zirconium cyclosilicate for up-titration of renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure: a case series. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab281.	0.3	3
11	Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. <i>Pharmacological Research</i> , 2021, 172, 105835.	3.1	19
12	Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400â€‰%000 patients from the UK Clinical Practice Research Datalink (CPRD). <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2203-2212.	1.4	15
13	Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions. <i>Journal of Clinical Medicine</i> , 2021, 10, 412.	1.0	4
14	Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. <i>American Heart Journal</i> , 2022, 243, 177-186.	1.2	19
15	Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population. <i>ESC Heart Failure</i> , 2021, 8, 691-696.	1.4	2
16	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	3.0	89
17	Effects of renin-angiotensin system inhibitors on the incidence of unplanned dialysis. <i>Hypertension Research</i> , 2022, 45, 1018-1027.	1.5	9
18	Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 758-770.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view. <i>Journal of Internal Medicine</i> , 2022, 291, 165-180.	2.7	18
20	A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain. <i>Journal of Medical Economics</i> , 2022, 25, 640-649.	1.0	3
21	Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1139-1149.	2.2	1
22	The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland. <i>PharmacoEconomics - Open</i> , 0, , .	0.9	2
23	Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. <i>BMC Nephrology</i> , 2022, 23, .	0.8	7
24	Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 5330.	1.0	3
25	Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2099-2106.	1.4	2
26	Risk-Benefit Balance of Renin-Angiotensin-Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 5828.	1.0	2
27	Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia. <i>Nutrients</i> , 2022, 14, 4614.	1.7	1
28	Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate. <i>Journal of Clinical Medicine</i> , 2022, 11, 7096.	1.0	0
29	A New Perspective to Longstanding Challenges with Outpatient Hyperkalemia: A Narrative Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2023, 10, 205435812211497.	0.6	1
30	Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. <i>BMC Nephrology</i> , 2023, 24, .	0.8	6
31	A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. <i>BMC Nephrology</i> , 2023, 24, .	0.8	2
32	A systematic review and meta-analysis of the clinical impact of stopping renin-angiotensin system inhibitor in patients with chronic kidney disease. <i>Hypertension Research</i> , 2023, 46, 1525-1535.	1.5	4
34	Nursing Care in Acute Decompensated Heart Failure (ADHF) Based on Levine's Conservation Model: A Case Study. , 2023, , 397-406.		0